A B S T R A C T The effect of estrogen and progestin on pituitary responsiveness to 150 ig synthetic luteinizing hormone-releasing factor (LRF) was assessed in premenopausal women receiving sequential (no= 12) and combination (n = 7) contraceptive steroids. A marked contrast in the time-course and maximal response to LRF was found; a prompt but quantitatively smaller luteinizing hormone (LH) response was seen during cyclic combination therapy, while a delayed (five times) but enhanced (fivefold) LH response was observed during estrogen segments of cyclic sequential therapy. For follicle-stimulating hormone (FSH), the maximum rise was also higher, and the peak response was similarly delayed in the latter group. The quantitative secretion in response to LRF for LH (area under the curve), but not for FSH, was significantly greater (P <0.01) in subjects receiving sequential, as compared to subjects receiving combination treatment. In both groups, characteristic gonadotropin responses to LRF were reproducible and were independent of the duration of treatment. Since LRF studies were performed during the estrogen segment of treatment cycle in subjects receiving sequential steroids, our data suggest that estrogen ex- 
INTRODUCTION
Despite the widespread application of hormone contraception, the precise temporal relationship between the feedback action of synthetic contraceptive steroids and pituitary gonadotropin secretion has yet to be defined. Previously, Kastin, Schally, Gual, Midgley, Bowers, and Diaz-Infante and Kastin, Schally, Gual and Arimura have shown that pretreatment with combined estrogen and progestin (Lyndiol) did not prevent the release of luteinizing hormone (LH)1 and follicle-stimulating hormone (FSH) in response to porcine luteinizing hormone-releasing factor (LRF) (1) and synthetic LRF (2) . This finding has led to their conclusion that most of the action of these compounds in suppressing gonadotropin levels must occur at the hypothalamus or higher central nervous system (CNS) centers (3 Table I . LRF studies were performed during estrogen segments of the treatment cycle (days 7-16) in 10 subjects receiving sequential treatment and (days 9-20) in 5 subjects receiving combination treatment. Repeated studies were performed in three subjects (Table I) .
Subjects were instructed to take the medication approximately 10-12 h before the study and were placed in bed in the ambulatory clinical research facility. Base-line blood samples were obtained at 15-min intervals for 1-3 h via an indwelling venous catheter. At zero time, an i.v. bolus of synthetic LRF (150 lsg) was administered and was followed by 15-min-interval blood sampling for 3 h. For this study, the same batch of highly purified synthetic LRF was prepared and utilized as previously described for human investigations (4, 6) .
Quantitative comparison of LH-FSH release in response to LRF between the two groups was made by calculation of the area under the curve above the base-line levels during the first 3 h after LRF stimulation.
Serum LH and FSH concentrations were measured by specific radioimmunoassay and are expressed as mIU/ml serum of second IRP-HMG (8, 9) . Relative potency of the IRP and pituitary standard LER 907 was 38 mIU/,ug for FSH and 210 mIU/,ug for LH. All samples from a single study were measured in duplicate in the same assay.
The two-tailed Student's paired t test was used for statistical analyses.
RESULTS
In subjects receiving combination estrogen and progestin treatment, LRF (150 ltg) induced a prompt increase in circulating LH and FSH with a time-course similar to that observed during the normal menstrual cycle (4). The mean peak concentration was reached at 30 min for LH (39.7±11.2 mIU/ml) and at 60 min for FSH (11.7±1.5 mIU/ml) ( Fig. 1 ). These incremental In contrast, a delayed (135 vs. 30 min) but enhanced peak (fivefold) with a sustained LH response to LRF was found in subjects receiving sequential estrogen and progestin (Fig. 1) . When compared with the responses seen in subjects receiving combination treatment, the difference for LH was significant by 90 min after LRF (P < 0.005), and the maximum rise for FSH was also higher and similarly delayed, but statistically it was not significant (Fig. 1) . The differences in the quantitative release and in the time-course between the two groups became more distinct when the data were analyzed as percent change from the control value (zero time). A diminished response for both LH and FSH within the first 60 min and a reversed event from 75-180 min was clearly shown in the sequential group as contrasted with the combination group (Fig. 2 ). These differences were significant for LH at 15-45 (P < 0.001), 60 (P < 0.01), and 135-180 min (P < 0.2) ; and for FSH at 30-45 (P < 0.01 ), 60 (P < 0.05), 150-165 (P < 0.02), and 180 min (P <0.1). In both groups, characteristic gonadotropin responses to LRF were reproducible in the same subjects (Fig. 3) and were independent of the duration of treatments (Table I ). Within our experimental design, a similar qualitative feature was seen in subjects tested on D. or D2. in the combination group and on D7 or D1e in the sequential group. Fig. 4 (2) . This finding has led to their conclusion that most of the action of these compounds in suppressing gonadotropin levels must occur at the hypothalamus or higher CNS centers (3) . However, effects of sequential contraceptive steroids were not evaluated. Our present study confirms their finding and has provided additional information which (10) , may exist and that pharmacological amounts of estrogen with relative constant circulating levels may suppress the acute releasable pool (first pool) and concomitantly enhance the slowly reactive system of gonadotropin release (chronic pool) within the population of pituitary gonadotropinproducing cells. The present finding supports the likelihood that an increased LH release in response to LRF from early to late follicular phase, observed in our earlier study, may be temporally related to a direct feedback action of estradiol on the gonadotropic cell (4). The lack of impairment of the initial-phase gonadotropin response to LRF during the menstrual cycle and the appearance of the latent phase of gonadotropin release in cyclic estrogen-treated subjects could be explained by a difference in the time-course and levels of incremental changes between endogenous estradiol and sequential contraceptive steroid treatment. Although these data have provided information about the complex interaction between pituitary gonadotropin and ovarian steroids, the precise nature responsible for the observed relationship requires further investigation. ACKNOWLEDGMENTS
